{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:22:19Z","timestamp":1787779339955,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005689","name":"G\u00f6teborgs L\u00e4kares\u00e4llskap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021548","name":"Drottning Silvias barnsjukhus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021548","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcf.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:30:28Z","timestamp":1787427028000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Once-daily hypertonic saline inhalation and airway clearance techniques in children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a prospective multicentre study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-7365","authenticated-orcid":false,"given":"Marcus","family":"Svedberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Imberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2026.08.006_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Taylor-Cousar JL: cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"10059","key":"10.1016\/j.jcf.2026.08.006_bib0002","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.006_bib0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.08.006_bib0004","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/apa.70498","article-title":"Improved quality of life in children with cystic fibrosis who received transmembrane conductance regulator modulators","volume":"115","author":"Svedberg","year":"2026","journal-title":"Acta Paediatr"},{"issue":"12","key":"10.1016\/j.jcf.2026.08.006_bib0005","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.jcf.2026.08.006_bib0006","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.08.006_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jcf.2026.08.006_bib0008","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.006_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1183\/09031936.00069712","article-title":"Consensus statement for inert gas washout measurement using multiple- and single- breath tests","volume":"41","author":"Robinson","year":"2013","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.006_bib0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00063198-199811000-00003","article-title":"Measurement of quality of life in cystic fibrosis","volume":"4","author":"Quittner","year":"1998","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.006_bib0011","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.006_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.08.006_bib0013","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2025.12.016","article-title":"Improved ventilation inhomogeneity and lower LCI variability under ETI: retrospective analysis in a pediatric cohort","volume":"25","author":"Arn-Roth","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.08.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71038","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on microbiology and antibiotic utilization in people with cystic fibrosis","volume":"60","author":"Williams","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2026.08.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70373","article-title":"Real-world evaluation of outcomes and safety of Elexacaftor\/Tezacaftor\/ivacaftor in pediatric patients with cystic fibrosis: a retrospective study","volume":"18","author":"Perrotta","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.jcf.2026.08.006_bib0016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/thoraxjnl-2021-216928","article-title":"Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis","volume":"77","author":"Horsley","year":"2022","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jcf.2026.08.006_bib0017","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1002\/ppul.26136","article-title":"Pulmonary exacerbations, airway pathogens, and long-term course of lung clearance index in children and young adults with cystic fibrosis","volume":"57","author":"Hatziagorou","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2026.08.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02686-2020","article-title":"Latzin P: longitudinal course of clinical lung clearance index in children with cystic fibrosis","volume":"58","author":"Frauchiger","year":"2021","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jcf.2026.08.006_bib0019","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing Treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326037203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:02:31Z","timestamp":1787778151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326037203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S1569199326037203"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.08.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-daily hypertonic saline inhalation and airway clearance techniques in children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor: a prospective multicentre study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}